摘要
目的:研究分析曲妥珠单抗联合多西他赛治疗HER2阳性的转移性乳腺癌的临床效果。方法:将2017年4月至2018年4月于本院收治的76例HER2阳性的转移性乳腺癌患者作为此次研究对象,以随机分组的形式将其分为两组,单一组38例患者予以多西他赛化疗方案,联合组38例患者予以曲妥珠单抗联合多西他赛化疗方案,治疗后对比两组患者治疗总有效率、不良反应发生率与炎症性因子水平。结果:1)联合组患者治疗总有效率94.7%高于单一组患者治疗总有效率78.9%,数据差异显著(P<0.05)。2)联合组患者不良反应发生率18.5%低于单一组患者不良反应发生率39.4%,数据差异显著(P<0.05)。3)联合组患者TNF-α、IL-1β、IL-6、IL-8炎性因子水平指标均低于单一组患者,数据差异显著(P<0.05)。结论:曲妥珠单抗联合多西他赛治疗HER2阳性的转移性乳腺癌的临床效果较为理想,且具有较高的安全性,降低了患者炎症性因子水平,治疗效果得到了临床与患者的认可。
Objective:The clinical effect of tritozumab combined with docetaxel in the treatment of HER2 positive metastatic breast cancer was analyzed.Methods:From April 2017 to April 2018, 76 patients with HER2 positive metastatic breast cancer were randomly divided into two groups. One group of 38 patients received docetaxel chemotherapy. 38 patients in the combined group were treated with tritozumab combined with docetaxel. After treatment, the total effective rate, the incidence of adverse reactions and the level of inflammatory factors were compared between the two groups.Results:1)The total effective rate of the combined group was 94.7%, which was significantly higher than that of the single group (78.9%, P < 0.05).2)The incidence of adverse reactions in the combined group (18.5%) was significantly lower than that in the single group (39.4%)( P < 0.05).3)The levels of TNF-α, IL-1 β and IL-6,IL-8 in the combined group were significantly lower than those in the single group ( P < 0.05).Conclusion:The clinical effect of tratozumab combined with docetaxel in the treatment of HER2 positive metastatic breast cancer is ideal and has high safety, which reduces the level of inflammatory factors in patients.
作者
刘海美
Liu Haimei(Medical Insurance Office of Heze Municipal Hospital of Shandong Province, Heze, Shandong 274000)
出处
《中外女性健康研究》
2019年第13期24-25,共2页
Women＇s Health Research
